Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terri Wrin

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2005
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionSimon D W Frost, Terri Wrin, Davey M Smith, et al.
The Journal of Infectious Diseases|June 25, 2004
Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infectionJason D Barbour, Frederick M Hecht, Terri Wrin, et al.
Plos One|January 18, 2013
Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolateKristin M Narayan, Nitish Agrawal, Sean X Du, et al.
Journal of Virology|September 20, 2013
Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfectionAntoine Chaillon, Gabriel A Wagner, N Lance Hepler, et al.
The Journal of General Virology|July 18, 2003
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapyJan Weber, Hector R Rangel, Bikram Chakraborty, et al.
The Journal of Infectious Diseases|March 28, 2003
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral controlSusan A Sufka, Guido Ferrari, Victoria E Gryszowka, et al.
Virology|October 10, 2009
Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoproteinSean X Du, Rebecca J Idiart, Ellaine B Mariano, et al.
Journal of Virology|February 21, 2012
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4Emilia Falkowska, Alejandra Ramos, Yu Feng, et al.
Virology|June 28, 2014
Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized miceCheryl A Stoddart, Sofiya A Galkina, Pheroze Joshi, et al.
The Journal of Infectious Diseases|January 25, 2002
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapySteven G Deeks, Rebecca Hoh, Robert M Grant, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Proceedings of the National Academy of Sciences of the United States of America|December 13, 2005
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionSimon D W Frost, Terri Wrin, Davey M Smith, et al.
The Journal of Infectious Diseases|June 25, 2004
Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infectionJason D Barbour, Frederick M Hecht, Terri Wrin, et al.
Plos One|January 18, 2013
Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolateKristin M Narayan, Nitish Agrawal, Sean X Du, et al.
Journal of Virology|September 20, 2013
Dynamics of viral evolution and neutralizing antibody response after HIV-1 superinfectionAntoine Chaillon, Gabriel A Wagner, N Lance Hepler, et al.
The Journal of General Virology|July 18, 2003
A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env) antiretroviral therapyJan Weber, Hector R Rangel, Bikram Chakraborty, et al.
The Journal of Infectious Diseases|March 28, 2003
Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral controlSusan A Sufka, Guido Ferrari, Victoria E Gryszowka, et al.
Virology|October 10, 2009
Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoproteinSean X Du, Rebecca J Idiart, Ellaine B Mariano, et al.
Journal of Virology|February 21, 2012
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4Emilia Falkowska, Alejandra Ramos, Yu Feng, et al.
Virology|June 28, 2014
Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized miceCheryl A Stoddart, Sofiya A Galkina, Pheroze Joshi, et al.
The Journal of Infectious Diseases|January 25, 2002
CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapySteven G Deeks, Rebecca Hoh, Robert M Grant, et al.
Pageof 11